scholarly journals Factors Associated with Adherence to Transdermal Nicotine Patches within a Smoking Cessation Effectiveness Trial

2017 ◽  
Vol 13 (1) ◽  
pp. 33-43 ◽  
Author(s):  
Jonnie Handschin ◽  
Brian Hitsman ◽  
Sonja Blazekovic ◽  
Anna Veluz-Wilkins ◽  
E. Paul Wileyto ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Strong Predictor ◽  
Term Treatment ◽  
Anxiety Symptoms ◽  
Effectiveness Trial ◽  
Patch Use ◽  
Nicotine Patches ◽  
Transdermal Nicotine ◽  
Long Term Treatment ◽  
Over Time

Introduction: Adherence to transdermal nicotine patches, one of the most popular and effective treatments for nicotine dependence, remains very low and is a strong predictor of cessation rates.Aims: This study examined individual factors related to adherence as well as differences over time between adherent (>85% of daily patch use) and non-adherent participants (<85% of daily patch use).Methods: We analysed data from 440 participants who received 8 weeks of 21 mg transdermal nicotine and four behavioural counselling sessions within an effectiveness trial that examined the effects of long-term treatment. Multiple logistical regression assessed baseline variables associated with patch adherence and generalised estimating equations (GEE) were used to evaluate changes in craving and withdrawal, depressive and anxiety symptoms, substitute and complementary reinforcers, and side effects between participants who were or were not adherent.Results: Adherence to patch use was strongly associated with smoking cessation at week 8 (p < 0.05). In a logistic regression model, being female, living with a child or children, and higher self-reported anxiety symptoms were predictive of lower patch adherence (p < 0.05). In the GEE analysis, adherence was significantly associated with a greater reduction in craving, a greater engagement in substitute reinforcers, and a greater decrease in complementary reinforcers over time (p < 0.05).Conclusions: Difficulties adhering to transdermal nicotine patches may be related to psychiatric comorbidity, difficulty managing nicotine craving, and challenges with engaging in substitute reinforcers and reducing exposure to complementary reinforcers. These constructs may serve as targets for interventions designed to increase treatment adherence.Trial registration: ClinicalTrials.gov Identifier: NCT01047527

scholarly journals Factors Associated with Adherence to Transdermal Nicotine Patches within a Smoking Cessation Effectiveness Trial – CORRIGENDUM

2017 ◽  
Vol 13 (3) ◽  
pp. 186-186 ◽  
Author(s):  
Jonnie Handschin ◽  
Brian Hitsman ◽  
Sonja Blazekovic ◽  
Anna Veluz-Wilkins ◽  
E. Paul Wileyto ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Online Version ◽  
Effectiveness Trial ◽  
Factors Associated ◽  
Nicotine Patches ◽  
Transdermal Nicotine

The above published article by Handschin et al. contains an error in the spelling of an author's name.Brain Hitsman, should read: Brian HitsmanThis error has now been rectified in the online version of this article.

scholarly journals Monthly Intramuscular Neridronate for the Treatment of Postmenopausal Osteoporosis: Results of a 6-Year Prospective Italian Study

2019 ◽  
Vol 2019 ◽  
pp. 1-8
Author(s):  
L. Guiducci ◽  
C. Vassalle ◽  
P. Parchi ◽  
S. Maffei
Keyword(s):  
Vitamin D ◽  
Calcium Supplementation ◽  
Bone Alkaline Phosphatase ◽  
Term Treatment ◽  
Mineral Density ◽  
Safe Alternative ◽  
Long Term Treatment ◽  
Effective Option ◽  
Monthly Administration ◽  
Over Time

Purpose. Oral bisphosphonates (BPs) are the most commonly used medications for osteoporosis (OP), but their poor gastrointestinal (GI) absorption and tolerance hamper compliance. Intramuscular (IM) neridronate (NE), an amino-BP, is an easy-to-administer, effective, and safe alternative to oral BPs. We assessed the 6-year effects of monthly IM NE on bone mineral density (BMD) and bone turnover biomarkers (BMs) in postmenopausal OP. Methods. This single-center, prospective study enrolled postmenopausal osteoporotic outpatients with gastric intolerance to BPs (based on Tuscany Region’s law GRT n. 836 20/10/2008). They received 25 mg IM NE once a month (with vitamin D and calcium if necessary) for 6 years. BMD was evaluated at lumbar spine (L1-L4), femoral neck (FN), and total femur (TF) at baseline (BL) and every 12 months afterwards. At BL, month 3, and every 12 months after BL, total and ionized calcium, vitamin D, parathyroid hormone 1-84, bone alkaline phosphatase (BALP), osteocalcin, and N- and C-terminal telopeptides were assayed. Results. Overall, 60 women (mean age: 62.3±7.5 years) received monthly IM NE for 6 years, with vitamin D and calcium supplementation in 81.3% of cases. Compared to BL, BMD increased significantly already after 1 year at all sites (4.5±0.9% for L1-L4, 4.5±0.8% for TF, and 2.1±0.6% for FN, P≤0.05), and the changes were maintained over time, whereas FN further improved up to year 3 and remained stable afterwards (P≤0.05). All BMs, except for total calcium and BALP, progressively decreased over time (P≤0.05). No fractures and significant adverse events were reported. Conclusion. The monthly administration of IM NE represents a manageable and effective option, in terms of BMD and bone BM improvement, for the long-term treatment of postmenopausal OP women with gastric intolerance to BPs. This trial is registered with ClinicalTrials.gov Identifier: NCT03699150.

The influence of offering free transdermal nicotine patches on quit rates in a local health department's smoking cessation program

2004 ◽  
Vol 29 (9) ◽  
pp. 1763-1778 ◽  
Author(s):  
Anthony J. Alberg ◽  
Ruth Stashefsky Margalit ◽  
Alyce Burke ◽  
Kimberly A. Rasch ◽  
Nell Stewart ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Smoking Cessation Program ◽  
Local Health ◽  
Nicotine Patches ◽  
Transdermal Nicotine

scholarly journals Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis

Neurology ◽  
2017 ◽  
Vol 88 (9) ◽  
pp. 832-841 ◽  
Author(s):  
Linard Filli ◽  
Björn Zörner ◽  
Sandra Kapitza ◽  
Katja Reuter ◽  
Lilla Lörincz ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Drug Efficacy ◽  
Term Treatment ◽  
Considerable Proportion ◽  
Open Label ◽  
Double Blind ◽  
Long Term Treatment ◽  
Drug Responsiveness ◽  
Over Time

Objective:To expand upon the limited knowledge of the long-term effects of prolonged-release (PR) fampridine in patients with multiple sclerosis (PwMS) regarding safety, walking improvements, and changes in drug responsiveness.Methods:Fifty-three PwMS who completed the FAMPKIN core study were included in this extension trial. Drug efficacy was assessed in an open-label and randomized double-blind, placebo-controlled study design with regular baseline assessments over a period of 2 years using the Timed 25-Foot Walk (T25FW), 6-Minute Walk Test (6MWT), and 12-item MS Walking Scale (MSWS-12) as outcome measures.Results:The data showed good tolerability and persisting efficacy of PR fampridine during long-term treatment in PwMS. Significant improvements in walking speed, endurance, and self-perceived ambulatory function were observed during open-label (T25FW: +11.5%; 6MWT: 10.7%; MSWS-12: 6.1 points) and double-blind controlled treatment with PR fampridine (T25FW: +13.1%; 6MWT: 11.9%; MSWS-12: 7.4 points). Several patients showed changes in drug responsiveness over time, resulting in an increased proportion of patients exceeding 10% or 20% improvements in walking measures after long-term treatment.Conclusions:Efficacy and tolerability data confirmed PR fampridine as a valuable long-term treatment for improving ambulatory function in gait-impaired PwMS. Similar results in open-label and double-blind phases reveal that the walking tests used are objective and reliable. The considerable proportion of patients in whom responsiveness to PR fampridine changed over time emphasizes the importance of regular reassessment of drug efficacy in clinical practice to optimize treatment. Such reassessments seem to be particularly important in patients with poor initial drug responses, as this group demonstrated enhanced responsiveness after long-term treatment.Clinicaltrials.gov identifier:NCT01576354.Classification of evidence:This study provides Class II evidence that PR fampridine significantly improved gait compared to placebo in a 2-week study in PwMS who had been using PR fampridine for 2 years.

scholarly journals Real-World, Long-Term Quality of Life Following Therapeutic OnabotulinumtoxinA Treatment

2016 ◽  
Vol 43 (5) ◽  
pp. 687-696 ◽  
Author(s):  
Mandar Jog ◽  
Theodore Wein ◽  
Meetu Bhogal ◽  
Sonja Dhani ◽  
Robert Miller ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Short Form ◽  
Health Utility ◽  
Primary Outcome Measure ◽  
Term Treatment ◽  
Subsequent Treatment ◽  
Long Term Treatment ◽  
Over Time

AbstractBackground:OnabotulinumtoxinA is an efficacious treatment option for patients with various conditions. Although studies have reported on the efficacy of onabotulinumtoxinA, quality of life (QoL) data are limited. This study evaluated QoL in patients treated with onabotulinumtoxinA across various therapeutic indications.Methods:MDs on BOTOX Utility (MOBILITY) was a prospective, multicenter, observational Canadian study in patients initiating (naïve) or receiving ongoing (maintenance) onabotulinumtoxinA treatment. Health utility was the primary outcome measure and was obtained from the Short Form-12 Health Survey using the Short Form-6D at baseline, week 4 posttreatment, and up to five subsequent treatment visits. The safety cohort included patients who received ≥1 onabotulinumtoxinA treatment.Results:The efficacy cohort included 1062 patients; the majority were Caucasian, female, and on maintenance onabotulinumtoxinA treatment. Adult focal spasticity (n=398), blepharospasm (n=81), cerebral palsy (n=22), cervical dystonia (n=234), hemifacial spasm (n=116), and hyperhidrosis (n=211) patients were included. Baseline health utility was generally higher in maintenance versus naïve patients; however, naïve patients showed the greatest improvements over time. Health utility was generally maintained or trended toward improvement across all cohorts, including maintenance patients who had been treated for up to 22 years before study entry. Eighteen of 1222 patients (2%) in the safety cohort reported 28 treatment-related adverse events; eight were serious in four patients.Conclusion:MOBILITY is the largest prospective study to date to provide QoL data over a variety of therapeutic indications following treatment with onabotulinumtoxinA. Although the QoL burden varies by disease, data suggest that long-term treatment may help improve or maintain QoL over time.

Meta-analysis of studies investigating one-year effectiveness of transdermal nicotine patches for smoking cessation

2007 ◽  
Vol 64 (23) ◽  
pp. 2471-2476 ◽  
Author(s):  
Seung Kwon Myung ◽  
Keun-Young Yoo ◽  
Seung Won Oh ◽  
Seong Hi Park ◽  
Hong Gwan Seo ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Meta Analysis ◽  
Nicotine Patches ◽  
Transdermal Nicotine ◽  
One Year
Sign in / Sign up

Export Citation Format

Share Document